Virbac SA (LON:0NM7)

Market Cap	2.51B -1.4%
Revenue (ttm)	1.29B +4.3%
Net Income	134.20M +17.2%
EPS	15.54 +17.0%
Shares Out	n/a
PE Ratio	19.19
Forward PE	16.88
Dividend	1.25 (0.42%)
Ex-Dividend Date	Jul 2, 2026

Volume	n/a
Open	357.75
Previous Close	358.00
Day's Range	355.00 - 359.00
52-Week Range	297.00 - 385.50
Beta	0.75
Analysts	n/a
Price Target	n/a
Est. Earnings	Mar 17, 2027

About Virbac

Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. The company offers Vikaly, a cat food designed for the management of feline chronic kidney disease; Prevexto that contains imidacloprid and flumethrin, providing long-lasting parasite protection collar for dogs and cats at risk of fleas, ticks, lice, and sandflies; Zenidog/Zenifel offers a fogger, spray, and non-electric ph...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1968
• Employees: 6,442
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0NM7

Financial Performance

In 2025, Virbac's revenue was 1.46 billion, an increase of 4.82% compared to the previous year's 1.40 billion. Earnings were 150.89 million, an increase of 3.85%.

Financial numbers in EUR

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 10, 2026

Data Sources Report a data error